[Lipid changes of fibrinogen and of platelet aggregation induced by etofibrate]. / Modificações lipídicas do fibrinogênio e da agregação plaqutária induzidas pelo etofibrato.
Arq Bras Cardiol
; 66(1): 33-5, 1996 Jan.
Article
em Pt
| MEDLINE
| ID: mdl-8731322
PURPOSE: To evaluate modifications on lipid profile, fibrinogen and platelet aggregation induced by etofibrate. METHODS: Twenty-one adult patients were studied. They all had primary hyperlipidemia and had already been on the AHA step I diet and placebo. Etofibrate (500mg/day) was administered for 60 days in the active phase, when lipid parameters, fibrinogen and platelet aggregation were measured. RESULTS: The % significant reductions were: total cholesterol (-9.50%), LDL-cholesterol (-7.88%), triglycerides (-19.07%), total cholesterol/HDL-cholesterol(-11.90%), LDL-cholesterol/HDL-cholesterol (-10.20%), fibrinogen (-12.79%), platelet aggregation with adrenaline (-24.02%), with ADP 1 mumol (-30.13%), and ADP 3 mumol (-24.51%). CONCLUSION: The beneficial effects of etofibrate were observed not only on the lipid profile but also on the thrombogenic parameters measured by fibrinogen and platelet aggregation.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fibrinogênio
/
Agregação Plaquetária
/
Lipídeos
/
Hipolipemiantes
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
Pt
Revista:
Arq Bras Cardiol
Ano de publicação:
1996
Tipo de documento:
Article
País de publicação:
Brasil